Skyclarys, a Reata Pharmaceuticals drug, is now approved for treating the rare neuromuscular disorder Friedreich’s ataxia. The decision makes the capsule the first therapy for a disease that’s rarer than either Duchenne muscular dystrophy or spinal muscular atrophy.
